Cite
HARVARD Citation
Novello, S. et al. (2018). Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Annals of oncology. pp. 1409-1416. [Online].